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Abstract
BACKGROUND: Diffuse anaplastic Wilms tumor (DAWT) is a rare, high-risk subtype that is often missed on diagnostic
needle biopsy. Somatic mutations in TP53 are associated with the development of anaplasia and with poorer survival,
particularly in advanced-stage disease. Early identification of DAWT harboring TP53 abnormalities could improve risk
stratification of initial therapy andmonitoring for recurrence.METHODS:Droplet digital polymerase chain reaction (ddPCR)
was used to evaluate 21 samples from 4 patients with DAWT. For each patient, we assessed TP53 status in frozen tumor,
matchedgermlineDNA,andcirculating tumorDNA (ctDNA) fromplasma, serum,andurinecollected throughout treatment.
RESULTS:Mutant TP53wasdetectable inctDNAfromplasmaandserum inall patients.Wedidnotdetect variant TP53 in the
same volume (200 μl) of urine. One patient displayed heterogeneity of TP53 in the tumor despite both histological sections
displaying anaplasia. Concentration of ctDNA from plasma/serum taken prenephrectomy varied significantly between
patients, ranging from 0.44 (0.05-0.90) to 125.25 (109.75-140.25) copies/μl. We observed variation in ctDNA throughout
treatment, and in all but onepatient, ctDNA levels fell significantly followingnephrectomy.CONCLUSION:Wedemonstrate
for the first time that ddPCR is an effective method for detection of mutant TP53 in ctDNA from children with DAWT even
when there is intratumoral somatic heterogeneity. This should be further explored in a larger cohort of patients, as early
detection of circulating variant TP53may have significant clinical impact on future risk stratification and surveillance.
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Introduction
Wilms tumor (WT) or nephroblastoma is the most common
childhood renal cancer, with 1 in 100,000 children diagnosed
annually [1]. In Europe, children are treated with neoadjuvant
chemotherapy prior to surgery as per The International Society of
Pediatric Oncology Renal Tumors Study Group (SIOP RTSG)
guidelines [2]. Conversely, in North America, children undergo
immediate surgery prior to chemotherapy in accordance with the
Children's Oncology Group (COG). For both groups, tumor
histology and stage dictate the intensity of postoperative treatment,
with chemotherapy and sometimes radiotherapy. Regardless of the
protocol used, overall survival approaches 90% [3].
Despite this excellent prognosis, approximately 15% of patients
relapse, and for the subgroup displaying high-risk histology, more
than one in four patients need intensified treatment for disease
recurrence [4]. Diffuse anaplasia (DAWT) is classified as high risk by
both SIOP RTSG and COG. Needle biopsy rarely captures anaplasia,
but it is found in 5%-10% of cases following surgical resection [5].
Approximately 60% of DAWTs have somatic mutations in the tumor
suppressor gene TP53 and/or 17p loss. Although these mutations
likely confer an increased risk of both relapse and mortality,
particularly in advanced tumor stage, genetic testing of surgically
resected tumors is not routinely performed [6,7].
At diagnosis, there are no radiological findings to clearly
differentiate a WT from other renal tumors or to differentiate the
subtype of WT. In most countries that follow the SIOP approach,
preoperative chemotherapy is commenced without a confirmatory
biopsy. Furthermore, biopsy provides limited diagnostic information
in part due to the high degree of genetic intratumoral heterogeneity
(ITH) found in WT [8,9]. In order to circumvent the issues of ITH
and the limitations and risks related to the biopsy procedure,
minimally invasive molecular biomarkers are urgently needed.
Circulating tumor DNA (ctDNA), shed by tumor cells and detectable
in a range of bodily fluids, is a promising candidate as it represents
contributions from multiple tumor subclones [10]. However, efforts to
characterize ctDNA in pediatric tumors have lagged behind the work
achieved in adult cancers.One principal limitation in detection of ctDNA
is its variable mutant allele fraction (MAF), among an abundant
background of cell-free DNA released by nontumor cells. Droplet digital
PCR (ddPCR) is an ideal tool for characterizing ctDNA as it provides a
limit of detection comparable toMAF.This technique partitions a sample
into 15,000-20,000 droplets, with PCR occurring in each droplet [11].
The number of DNA templates within each droplet is modeled by a
Poisson distribution, and by quantifying the fraction of positive droplets,
absolute DNA levels can be determined without extrapolation from a
standard curve [12]. Due to the relative concentrations of targets and
inhibitors in each droplet, ddPCR is more resistant to inhibition and
more reproducible at low target concentrations than real-time quantitative
PCR, making it attractive for diagnostic applications [13].
The purpose of this study was to test the feasibility of ctDNA
detection in children with high-risk DAWT using plasma, serum, and
urine collected throughout treatment.
Materials and Methods
Patients
All patients with a diagnosis of WT were enrolled in the UK-wide
Improving Population Outcomes for Renal Tumours of Childhood
(IMPORT) study. Informed consent to undertake genetic testing of
samples was obtained as part of the study, which was approved by the
national research ethics committee (London Bridge REC 12/LO/
0101). Normal kidney and multisampled tumor tissues were collected
at surgery, while blood and urine were collected at up to five
treatment time points: diagnosis, midchemotherapy, preoperative,
postoperative, and end of treatment. Patients were treated with
preoperative chemotherapy regimens according to stage as per SIOP
WT 2001. Nonmetastatic cases (stages I-III) received vincristine/
actinomycin-D for 4 weeks, with doxorubicin added for metastatic
disease (stage IV) for 6 weeks. Following nephrectomy, patients with
focal or diffuse anaplasia were risk stratified to intermediate- or
high-risk subgroups, respectively, and postoperative treatment was
further refined according to stage of disease at surgery.
DNA Extraction
All samples used for tumor DNA extraction were fresh-frozen
specimens obtained at nephrectomy and stored at −80°C. Specimens
underwent centralized histology review to confirm stage and
histology, and those with tumor content of more than 50% were
utilized for the study [14]. Tumor DNA and germline DNA from
normal tissue were extracted by standard methods using either a
standard detergent lysis/phenol-chloroform technique or the
DNAeasy Blood and Tissue Kit (Qiagen). Germline DNA from
cell fraction was extracted with the QIAamp DNA Blood Midi Kit
(Qiagen). DNA was stored at −20°C. Extraction of ctDNA from 200
μl of plasma, serum, and urine supernatant was carried out with the
Plasma/Serum Cell-free Circulating DNA Purification Mini Kit
(Norgen) and the Circulating Nucleic Acid Kit (Qiagen) as per
protocol. Elution volumes were 50 μl and 75 μl for the Norgen and
Qiagen kits, respectively. Quantification and further quality control
of tumor and germline DNA were undertaken with a NanoDrop
spectrophotometer (Thermo Fisher Scientific), Qubit fluorometer
(Thermo Fisher Scientific), and agarose gel.
Sequencing of Tumor and Germline DNA
For TP53mutational analysis, Sanger sequencing of tumor DNA was
carried out by Great Ormond Street Hospital Genetics. Bidirectional
sequencing was undertaken for all 11 exons of the gene. For the five
patients with TP53 mutations, we performed Sanger sequencing on
germline DNA. PCR amplification products were run on an agarose gel
prior to clean-up with Illustra ExoStar 1-Step (GE Healthcare Life
Sciences). Cleaned PCR products were sequenced using the BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) on an ABI
PRISM 3130 Genetic Analyzer (Applied Biosystems). Sequences were
examined both manually and electronically using ApE (v2.0.49 Wayne
Davis, University of Utah) and 4peaks (v1.8 Mekentosi, Amsterdam)
prior to genome alignment to GRCh37 with Blat [13] and functionally
annotated with Annovar [14]. Single nucleotide polymorphisms (SNPs)
were excluded if present in The Database of Single Nucleotide
Polymorphisms (dbSNP) [15].
ddPCR
In four out of the five cases with TP53 mutations, assays with
sequence-specific primers and TaqMan-based probes for mutant and
wild-type alleles were purchased (PrimePCR ddPCR Mutation Assay
Bio-Rad for TP53). Primer and probe sequences are not provided by
Bio-Rad, but amplicon context sequence and length for each assay are as
follows: p.R273C 17:7,577,060-7,577,182 65 nt; p.R337C
17:7,573,957-7,574,079 79 nt; p.R248Q 17:7,577,477-7,577,599 62
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nt; p.H197L 17:7,578,333-7,578,455 65 nt. To assess optimum annealing
temperature, each assay was run on a temperature gradient with germline
DNA and a 50:50mix of tumorDNA spiked into germlineDNA. Each
ddPCRmixture wasmade up of 11μl 2× ddPCR Supermix (No dUTP;
Bio-Rad), 1.1 μl mutant-specific FAM probe, 1.1 μl wild-type–specific
HEX probe, 0.5 μl restriction enzyme (MseI or HaeIII; New England
BioLabs), 0.5 μl nuclease-free water, and 8.8 μl sample DNA. Twenty
microliters of ddPCR mixture was partitioned into droplets using the
QX100 Droplet Generator (Bio-Rad). The thermal cycling profile was
95°C for 10 minutes, followed by 40 cycles of 94°C for 30 seconds and
52°C for 1 minute, then 1 cycle of 98°C for 10 minutes. Droplets were
read on a QX100 Droplet Reader (Bio-Rad). Three technical replicates
were used for each sample, as well as no template and positive controls
(tumor DNA with mutant TP53). QuantaSoft software (version
1.3.2.0, Bio-Rad) was used to set thresholds manually by evaluating
maximum separation between positive and negative clusters in control
wells. Data are presented in accordance with minimum reporting
guidelines for digital PCR studies [16]. Raw data were exported into R
Studio and plotted with the ggplot2 package (H. Wickham. ggplot2:
Elegant Graphics for Data Analysis. Springer-Verlag New York, 2009).
MAF is calculated by dividing the concentration of the mutant allele by
the sum of the concentrations of the mutant and wild-type alleles.
Calculating the MAF normalizes the mutant allele signal against the
background of wild-type alleles and represents the data as would be
expected in a next-generation sequencing (NGS)–based assay.
Results
Patient Demographics
Ten patients from the IMPORT study were identified with WT
displaying focal or diffuse anaplasia (confirmed by central histology
review) and with plasma, serum, and urine collected at more than one
time point. The clinicopathological information for each case is shown in
Table 1. None of the five patients with wild-type TP53 relapsed, while
three of five patients with TP53 mutations died of their disease.
Sanger Sequencing and ddPCR of Tumor Tissue
Sanger sequencing of tumor DNA identifiedTP53mutations in five
patients. Multiple spatially distinct tumor samples from each patient
were also analyzed on an NGS panel that included TP53 as part of
another experiment. The TP53 mutation in case 10 was subclonal,
while all other cases 1, 2, 6, and 9 were homogenous for mutant TP53
(data not shown). Only specimens with anaplasia were used for analysis.
There is no single hotspot locus for mutant TP53 in WT, and each
patient had individual mutations as shown in Table 1. Matched
germline DNA from cell fraction or normal kidney displayed the
Table 1. Clinicopathological Details for the Included Patients with Wilms Tumor, Including TP53 Status
Case Age at Diagnosis (Months) Sex Biopsy Histology Pathological Local Stage Metastatic at Diagnosis Relapse Died of disease TP53 status
1 58 F no anaplasia DAWT III 1 1 1 p.R248Q
2 58 F no anaplasia DAWT I 0 1 1 p.E285K
3 47 F no anaplasia DAWT III 0 0 0 wild type
4 53 F no anaplasia focal anaplasia I 0 0 0 wild type
5 19 F no anaplasia DAWT I 0 0 0 wild type
6 45 F no anaplasia DAWT III 1 1 1 p.R337C
7 75 M no anaplasia DAWT 1 0 0 0 wild type
8 71 M no anaplasia DAWT II 0 0 0 wild type
9 117 F diffuse anaplasia DAWT I 1 0 0 p.R273C
10 108 F unknown DAWT III 0 0 0 p.H179L
Table 2. Mean Concentration (copies/μl) of TP53 Mutant ctDNA for Each Sample
Case Number Time Point Sample Type Concentration (copies/μL) Confidence Interval (copies/μL)
1 PrO Serum 0.44 0.05-0.90
PsO Serum 6.63 4.93-8.15
EoT Urine 0.00 0.00-0.21
6 Dx Plasma 125.25 109.75-140.25
Dx Serum 121.00 98.00-140.50
Dx Urine 0.13 0.00-0.43
MC Plasma 15.20 11.43-18.70
MC Serum 16.20 12.48-19.80
MC Urine 0.07 0.00-0.34
PsO Plasma 0.00 0.00-0.23
PsO Serum 0.14 0.00-0.46
PsO Urine 0.00 0.00-0.17
9 Dx Plasma 20.58 16.25-24.33
Dx Serum 18.98 10.78-24.65
MC Plasma 4.53 2.18-6.58
PsO Plasma 0.42 0.00-0.92
PsO Urine 0.00 0.00-0.23
10 MC Plasma 1.93 0.14-3.23
PrO Plasma 1.29 0.34-1.96
PrO Urine 0.00 0.00-0.27
PsO Plasma 0.07 0.00-0.36
Time points as follows: Dx, diagnosis; MC, midchemotherapy; PrO, preoperative; PsO, postoperative; EOT, end of treatment. Wild-type TP53 from cell free DNA is not shown.
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wild-type allele, confirming the mutations as somatic changes. Tumor
samples were run as positive controls during the ddPCR experiments,
and all samples had mutant TP53 in the tumor (data not shown).
ddPCR of ctDNA from Plasma, Serum, and Urine
Mutations in TP53 from ctDNA were detectable from the four
cases with mutation-specific Bio-Rad assays. For case 2, there was no
commercially available mutation-specific assay.
Concentration varied significantly between patients (Table 2). The
most abundant mutant ctDNA was found in case 6 at diagnosis, both
in plasma and in serum, with a concentration of 125.25
(109.75-140.25) copies/μl and 121.00 (98.00-140.50) copies/μl,
respectively. Case 6 had lung metastases at diagnosis, with progression
of disease and new nodules postoperatively. The absence of detectable
ctDNA postoperatively suggests that the high levels were derived from
the primary tumor rather than metastatic deposits, as these were not
removed during nephrectomy. All patients had detectable ctDNA
prenephrectomy; we are unable to comment on chemonaive samples
as, for two of the cases, we did not receive samples at diagnosis.
In three out of four cases, MAF decreased following nephrectomy
(Figure 1). In case 1, ctDNA concentration increased from 0.44
(0.05-0.90) copies/μl to 6.63 (4.93-8.15) copies/μl after nephrecto-
my. We cannot rule out that the high concentration postoperatively is
due to manipulation of the tumor during surgery. However, owing to
the very short half-life of ctDNA, this effect is likely to be negligible.
This patient has stage III disease and relapsed 339 days postopera-
tively. In case 1 and case 10, wild-type TP53 (as assessed by cell-free
DNA levels) increased postoperatively.
Genomic contamination, thought to be from lysed blood cells, is
greater in serum than in plasma (Supplementary Figure 1).
Figure 1.MAF from serum and plasma for each case varies during treatment. Time points as follows: 1, diagnosis; 2, mid-chemotherapy;
3, pre-operative; 4, post-operative; and 5, end of treatment. MAF is calculated as mutant allele concentration divided by total
concentration. Error bars represent the range of MAFs produced within the confidence intervals of the mutant and wild-type allele
concentrations. Urine ctDNA is not shown.
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Concentration of ctDNA was significantly lower in 200 μl of urine
supernatant than those from the same volume of plasma or serum
(Table 2). The concentration of mutant ctDNA extracted from 1.8
ml of urine from case 1 postoperatively was 35.50 (32.25-38.75)
copies/μl.
Comparison of extraction kits (Qiagen circulating nucleic acid kit
versus Norgen Plasma/Serum Cell-free Circulating DNA Purification
Mini Kit) was undertaken in two cases with four samples overall.
Results are consistent with a previous study and demonstrate
comparable ctDNA yields (Supplementary Figure 2) [17].
Discussion
Our explorative study demonstrates that collection and analysis of
bodily fluids taken from children with WT are achievable. Further,
mutant TP53 is detectable in ctDNA from plasma and serum in
patients with DAWT, though not from the same volume of urine.
Although somaticTP53mutations are infrequent in childhood cancer,
pediatric pan-cancer analyses have identified TP53 as the most frequent
pathogenic constitutional mutation [18–20]. There are over 200 SNPs in
the gene, with some of these variants likely predisposing to cancer [21]. In
adults, somatic alterations inTP53 are the commonest genetic event, with
six frequently observed hotspot residues [22]. Two of the mutations we
identified (p.R248Q and p.R273C) align to data from 25,902 patients
showing that these sites are the two most common loci for TP53
mutations [23,24]. Regarding the amino acid residue R248, recurrent
TP53 mutations in WT have been observed at this locus [24]. Three
mutations (p.R248Q, p.R273C, and p.H179L) are considered to be gain
of function (GOF) and are associated with a highly aggressive phenotype,
while p.R337C is thought to be a nonfunctional mutant [25].
Mutations in TP53 are seemingly associated with a higher risk of
relapse and death for children with advanced-stage anaplastic WT
[3,4]. Originally thought to be pathognomonic for DAWT, a recent
analysis of 84 fatal cases found that 26% of nonanaplastic tumors
harbored mutations in TP53 [26]. There are no studies that have
assessed circulating TP53 status in nonanaplastic fatal tumors, but
this is clearly an avenue that requires exploration. With a mutational
spectrum from GOF to nonfunctional mutants, any decisions to
intensify therapy for children with mutant TP53 are likely to be
complex. As DAWT is relatively uncommon, with only around 150
cases annually in Europe and America, collaboration is vital in
addressing these clinical questions.
A further possible merit in assessment of TP53 status is targeted
therapy [27]. Early-phase trials in adult relapsed/refractory solid and
hematological malignancies are ongoing to test both TP53 recombinant
adenoviral human gene therapy as well as inhibitors of MDM2/MDMX,
negative regulators of p53 [28]. Interestingly, some patients with GOF
mutants have demonstrated response to MDM2/MDMX targeted
therapy, although there remains the theoretical risk that these inhibitors
could increase levels of mutant TP53 and drive cancer progression [28].
Our study was conducted as a proof of principle and hence was
carried out on a small number of patients (n = 4) and their associated
ctDNA samples (n = 21). Although, to date, 446 patients have been
recruited to the IMPORT study, only 8%-10% are expected to have
anaplastic WT, and only a minority of these patients had both tumor
sampling and samples from which to extract ctDNA (n = 10). A
further limitation is that samples were not taken at identical time
points for each patient. This is due to the intrinsic difficulties
associated with venous and urine sampling in young children,
complicated by multicenter sample collection, each having variable
resources. Due to genomic contamination, plasma is preferential to
serum in applications such as NGS where the mutant may be
obscured by the wild-type allele. For clinical utility, urinary ctDNA
would be preferable to plasma as sampling is minimally invasive. We
were able to detect mutant TP53 in ctDNA from 1.8 ml of urine
collected from case 1. A recent analysis in children with PIK3-
CA-related overgrowth spectrum syndrome found that PIK3CA
variants were detectable by ddPCR in 3 ml of urine from five of eight
patients [29]. Similar results have been demonstrated in adult
urological malignancies including renal cell carcinoma where, like
WT, cells may not be in direct contact with urine [30].
At the time of experimental design, to our knowledge, there were no
published data describing either DNA yields or MAFs in ctDNA from
patients with early-stage WT. As such, ddPCR was chosen for its limit of
detection. However, in its current form, ddPCR is unlikely to be of clinical
use for determining TP53 status in WT, as each patient requires a
mutation-specific assay. The issues with a personalized assay involve
unknownperformanceof bespoke primer sets and cost. Itwas decidednot to
design a mutation-specific assay for case 2 as this process would have lacked
the experimental validation of commercially produced sets. A targetedNGS
panel would permit analysis of the entire TP53 gene, and we have shown
that MAFs in this cohort are large enough to allow the detection of
circulatingTP53mutations. GenomicDNA contamination can be reduced
with size selection during library preparation, as ctDNA is fragmented [31].
A further merit in ctDNA is that it captures different tumor clones and
could be used in lieu of tumor multisampling. Though ctDNA from a
larger cohort of patients with WT needs to be characterized to ensure all
driver subclonal mutations are detectable. In patients with recurrent
hotspot mutations in the microRNA processing genes (DROSHA,
DGCR8) or the transcription factors SIX1/SIX2, ddPCR may one day
play a role in monitoring via serial liquid biopsies [32,33].
WT is a genetically heterogeneous group, and the current list of
WT-related cancer genes is fast approaching 40 [32–34]. However,
few of these genes are linked as strongly with clinical outcome as
mutant TP53 [6,7,26]. In the future, NGS-based methods could be
employed to screen blood/urine collected at diagnosis for TP53
mutations, allowing early intensification of preoperative chemother-
apy for this poorer prognostic group. In addition, ctDNA could be
monitored throughout treatment and used for surveillance post end of
treatment. The primary aim of our investigation was as a feasibility
study, and we have shown that mutant circulating TP53 is detectable
in children with WT, even in low-burden disease and regardless of
whether the underlying mutation is subclonal or homogeneous.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tranon.2018.08.006.
Acknowledgements
We thank all the families who consented to provide tissues for
research and the many clinicians involved in sample collection,
including members of the ECMC Paediatric network.
References
[1] Breslow N, Olshan A, Beckwith JB, and Green DM (1993). Epidemiology of
Wilms tumor. Med Pediatr Oncol 21, 172–181.
[2] van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H,
Furtwängler R, Verschuur AC, Vujanic GM, Leuschner I, Brok J, and Rübe C,
et al (2017). Position paper: rationale for the treatment of Wilms tumour in the
UMBRELLA SIOP–RTSG 2016 protocol. Nat Rev Urol 14, 743–752.
[3] Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM,
Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, and Vujanic
Translational Oncology Vol. 11, No. xx, 2018 Somatic TP53 Mutations in Anaplastic Wilms Tumor Treger et al. 1305
G, et al (2015). Omission of doxorubicin from the treatment of stage II-III,
intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label,
non-inferiority, randomised controlled trial. Lancet 386, 1156–1164.
[4] Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van den
Heuvel-Eibrink M, and Pritchard-Jones K (2015). Advances in Wilms tumor
treatment and biology: progress through international collaboration. J Clin Oncol
33, 2999–3007.
[5] VujanićGM, Kelsey A, Mitchell C, Shannon RS, and Gornall P (2003). The role
of biopsy in the diagnosis of renal tumors of childhood: Results of the UKCCSG
Wilms tumor study 3. Med Pediatr Oncol 40, 18–22.
[6] Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G,
Perlman E, Anderson JR, Grundy P, and Dome JS, et al (2014). TP53
mutational status is a potential marker for risk stratification in Wilms tumour
with diffuse anaplasia. PLoS One 9e109924.
[7] Ooms AHAG, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Meerzaman
D, Chen Q-R, Hsu CH, Yan C, and Nguyen C, et al (2016). Significance of
TP53 mutation in wilms tumors with diffuse anaplasia: a report from the
Chi ldren' s Oncology Group. Clin Cancer Re s . https : / /do i .
org/10.1158/1078-0432.CCR-16-0985.
[8] Cresswell GD, Apps JR, Chagtai T, Mifsud B, Bentley CC, Maschietto M,
Popov SD, Weeks ME, Olsen ØE, and Sebire NJ, et al (2016). Intra-tumor
genetic heterogeneity in Wilms tumor: clonal evolution and clinical implications.
EBioMedicine 0, 991–1000.
[9] Mengelbier LH, Karlsson J, Lindgren D, Valind A, Lilljebjörn H, Jansson C,
Bexell D, Braekeveldt N, Ameur A, and Jonson T, et al (2015). Intratumoral
genome diversity parallels progression and predicts outcome in pediatric cancer.
Nat Commun 6, 6125.
[10] Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R,
Le Quesne J, Moore DA, Veeriah S, and Rosenthal R, et al (2017). Phylogenetic
ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451.
[11] Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz
AJ, Bright IJ, Lucero MY, Hiddessen AL, and Legler TC, et al (2011).
High-throughput droplet digital PCR system for absolute quantitation of DNA
copy number. Anal Chem 83, 8604–8610.
[12] Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, Bhat S, and
Emslie KR (2012). Evaluation of a droplet digital polymerase chain reaction
format for DNA copy number quantification. Anal Chem 84, 1003–1011.
[13] Dingle TC, Sedlak RH, Cook L, and Jerome KR (2013). Tolerance of
droplet-digital PCR vs real-time quantitative PCR to inhibitory substances. Clin
Chem 59, 1670–1672.
[14] Vujanić GM, Sandstedt B, Kelsey A, and Sebire NJ (2009). Central pathology
review in multicenter trials and studies. Cancer 115, 1977–1983.
[15] Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, and
Sirotkin K (2001). dbSNP: the NCBI database of genetic variation. Nucleic Acids
Res 29, 308–311.
[16] Huggett JF, Foy CA, Benes V, Emslie K, Garson JA, Haynes R, Hellemans J,
Kubista M, Mueller RD, and Nolan T, et al (2013). The digital MIQE
guidelines: minimum information for publication of quantitative digital PCR
experiments. Clin Chem 59, 892–902.
[17] Mauger F, Dulary C, Daviaud C, Deleuze J-F, and Tost J (2015). Comprehensive
evaluation of methods to isolate, quantify, and characterize circulating cell-free DNA
from small volumes of plasma. Anal Bioanal Chem 407, 6873–6878.
[18] Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, Hedges D,
Ma X, Zhou X, and Yergeau DA, et al (2015). Germline mutations in
predisposition genes in pediatric cancer. N Engl J Med 373, 2336–2346.
[19] Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, Zhou X, Li Y,
Rusch MC, and Easton J, et al (2018). Pan-cancer genome and transcriptome
analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555,
371–376.
[20] Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva
VA, Johann PD, Balasubramanian GP, Segura-Wang M, and Brabetz S, et al
(2018). The landscape of genomic alterations across childhood cancers. Nature
555, 321–327.
[21] Whibley C, Pharoah PDP, and Hollstein M (2009). p53 polymorphisms: cancer
implications. Nat Rev Cancer 9, 95–107.
[22] Baugh EH, Ke H, Levine AJ, Bonneau RA, and Chan CS (2018). Why are there
hotspot mutations in the TP53 gene in human cancers? Cell Death Differ 25,
154–160.
[23] Freed-Pastor WA and Prives C (2012). Mutant p53: one name, many proteins.
Genes Dev 26, 1268–1286.
[24] Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG,
Ward S, Dawson E, and Ponting L, et al (2017). COSMIC: somatic cancer
genetics at high-resolution. Nucleic Acids Res 45, D777–D783.
[25] Mello SS and Attardi LD (2013). Not all p53 gain-of-function mutants are
created equal. Cell Death Differ 20, 855–857.
[26] Wegert J, Vokuhl C, Ziegler B, Ernestus K, Leuschner I, Furtwängler R, Graf N,
and Gessler M (2017). TP53 alterations in Wilms tumour represent progression
events with strong intratumour heterogeneity that are closely linked but not
limited to anaplasia. J Pathol Clin Res 3, 234–248.
[27] Brok J, Pritchard-Jones K, Geller JI, and Spreafico F (2017). Review of phase I
and II trials for Wilms' tumour—can we optimise the search for novel agents? Eur
J Cancer 79, 205–213.
[28] Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, and Lim E (2016). Clinical
overview of MDM2/X-targeted therapies. Front Oncol 6, 7.
[29] Biderman Waberski M, Lindhurst M, Keppler-Noreuil KM, Sapp JC, Baker L,
Gripp KW, Adams DM, and Biesecker LG (2018). Urine cell-free DNA is a
biomarker for nephroblastomatosis or Wilms tumor in PIK3CA-related
o v e r g r ow th s p e c t r um (PROS ) . Gen e t Me d . h t t p s : / / d o i .
org/10.1038/gim.2017.228.
[30] Di Meo A, Bartlett J, Cheng Y, Pasic MD, and Yousef GM (2017). Liquid
biopsy: a step forward towards precision medicine in urologic malignancies. Mol
Cancer 16(1), 80.
[31] Shu Y, Wu X, Tong X, Wang X, Chang Z, Mao Y, Chen X, Sun J, Wang Z, and
Hong Z, et al (2017). Circulating tumor DNA mutation profiling by targeted
next generation sequencing provides guidance for personalized treatments in
multiple cancer types. Sci Rep 7, 583.
[32] Walz AL, Ooms A, Gadd S, Gerhard DS, Smith MA, Guidry Auvil JM, Guidry
Auvil JM, Meerzaman D, Chen Q-R, and Hsu CH, et al (2015). Recurrent
DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology
Wilms tumors. Cancer Cell 27, 286–297.
[33] Wegert J, Ishaque N, Vardapour R, Geörg C, Gu Z, Bieg M, Ziegler B,
Bausenwein S, Nourkami N, and Ludwig N, et al (2015). Mutations in the
SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex
underlie high-risk blastemal type Wilms tumors. Cancer Cell 27, 298–311.
[34] Gadd S, Huff V, Walz AL, Ooms AHAG, Armstrong AE, Gerhard DS, Smith
MA, Auvil JMG, Meerzaman D, and Chen Q-R, et al (2017). A Children's
Oncology Group and TARGET initiative exploring the genetic landscape of
Wilms tumor. Nat Genet 49, 1487–1494.
1306 Somatic TP53 Mutations in Anaplastic Wilms Tumor Treger et al. Translational Oncology Vol. 11, No. xx, 2018
